Produkty 88901-46-6

CAS 88901-46-6 występuje w naszej ofercie pod nazwami: Mogroside I A1, Mogroside I A1, ≥98%, ≥98%, Mogroside I A1, 99.77%. Oferty producentów: Biosynth, Chemat, MedChemExpress. Dostępne opakowania: 5mg, 2mg, 10mg, 25mg, 50mg, 1mg, 10 mg, 5 mg.

Mogroside I A1
Biosynth
  • opakowanie: 5mg, 2mg, 10mg, 25mg
  • Warianty: 5
Zobacz produkt
Mogroside I A1, ≥98%, ≥98%
Chemat
  • opakowanie: 1mg, 5mg, 10mg, 25mg
  • Warianty: 4
od 1312,40
Zobacz produkt
Mogroside I A1, 99.77%
MedChemExpress
  • opakowanie: 10 mg, 5 mg, 1 mg
  • Warianty: 3
od 1271,71
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(2S,3R,4S,5S,6R)-2-[(3R,6R)-6-[(3S,8S,9R,10R,11R,13R,14S,17R)-3,11-dihydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-hydroxy-2-methylheptan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol (CAS 88901-46-6) to związek chemiczny o wzorze sumarycznym C36H62O9 i masie molowej 638.9 g/mol. Nazwa systematyczna IUPAC: (2S,3R,4S,5S,6R)-2-[(3R,6R)-6-[(3S,8S,9R,10R,11R,13R,14S,17R)-3,11-dihydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-hydroxy-2-methylheptan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol. InChIKey: UNCMRQFSKAVFQU-QZGPORMMSA-N.

Dane identyfikacyjne
Wzór sumarycznyC36H62O9
Masa molowa638.9 g/mol
Nazwa IUPAC(2S,3R,4S,5S,6R)-2-[(3R,6R)-6-[(3S,8S,9R,10R,11R,13R,14S,17R)-3,11-dihydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-hydroxy-2-methylheptan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
InChIKeyUNCMRQFSKAVFQU-QZGPORMMSA-N
SMILESC[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@H]2CC[C@@]3([C@@]2(C[C@H]([C@@]4([C@H]3CC=C5[C@H]4CC[C@@H](C5(C)C)O)C)O)C)C

Dane obliczone przez PubChem (NCBI)

Synonimy: Mogroside I-A1, Mogroside I A1, mogroside IA, Mogroside Ia1, 3alpha-Hydroxymogroside IA1, orb2665611
Izomery (ten sam wzór sumaryczny)
(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol C36H62O9
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2S)-6-methyl-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,6,12-trihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxyoxane-3,4,5-triol C36H62O9
(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol C36H62O9
(2R,3R,4S,5S,6R)-2-[[(3S,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol C36H62O9
(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(E)-6-hydroxy-6-methylhept-2-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol C36H62O9